Please use this identifier to cite or link to this item:
|Title:||Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.|
|Authors:||Goodwin, Mark D;Dobson, Julie E;Sirlin, Claude B;Lim, Beng Ghee;Stella, Damien L|
|Affiliation:||Department of Radiology, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australia. email@example.com|
|Citation:||Radiographics : A Review Publication of the Radiological Society of North America, Inc; 31(6): 1547-68|
|Abstract:||The use of gadolinium-based hepatocyte-specific contrast agents (HSCAs) has increased markedly since their introduction, and hepatocellular phase imaging performed with an HSCA is now a key part of the standard magnetic resonance (MR) imaging work-up for focal liver lesions. An understanding of the mechanisms of action of HSCAs helps ensure their effective use. The optimal delay for hepatocellular phase image acquisition differs between the two currently available HSCAs, gadoxetic acid and gadobenate dimeglumine, and MR imaging protocols must be adjusted accordingly. In addition, familiarity with typical and atypical appearances of benign and malignant focal liver lesions at HSCA-enhanced hepatocellular phase MR imaging, along with knowledge of the processes that are most likely to produce atypical appearances, is required to achieve optimal diagnostic accuracy.|
|Internal ID Number:||21997981|
|Subjects:||Contrast Media.diagnostic use|
Gadolinium DTPA.diagnostic use
Magnetic Resonance Imaging.methods
Meglumine.analogs & derivatives.diagnostic use
Organometallic Compounds.diagnostic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.